SDCBP and prostate carcinoma: In prostate cancer, syntenin-1 activates STAT3 by its interaction with IGF-1R; thus, it promotes invasion and cell migration, which is also regulated by Rac by the interaction with syntenin-1 and syndecan-2 [9].